VaxCell-Bio said it has signed a tripartite convergence business agreement with Jeonnam Bio Research Center (JBRC) and Thermo Fisher Scientific Solutions LLC to organically cooperate throughout the entire cycle to develop innovative cell therapy drugs.
The main areas of cooperation include the exchange of cell therapy research and development technology, solutions for cell therapy production and efficiency enhancement, process development and new good manufacturing practice (GMP) expansion, cell therapy production and quality control training programs, and infrastructure construction in specialized bio-complexes and advanced medical complexes, such as Hwasun Vaccine Special Zone.
“We expect that VaxCell-Bio's leading immunotherapy technology will become a cradle of innovation in immunotherapy technology through integration with JBRC's vaccine and cell therapy R&D facilities and contract manufacturing services, and Thermo Fisher's advanced cell therapy R&D equipment and professional training programs," VaxCell-Bio CEO Lee Je-jung said. “We will also join forces to build related infrastructure such as the Hwasun Vaccine Special Zone.”
VaxCell-Bio is a company specializing in the development of immunotherapy, currently developing the Vax-NK cell therapy platform and an immunotherapy platform for animals.
The company is finalizing phase 2a clinical trials for liver cancer patients using the Vax-NK platform and is preparing separate clinical trials for pancreatic cancer. Additionally, they have launched four types of pet immune function supplements.
JBRC, located within the Hwasun Vaccine Bio Industrial Complex, leads and supports the biopharmaceutical industry in Korea's southern region by providing optimal services for the development and industrialization of biopharmaceuticals.
The center’s mission and goal is attracting specialized bio-complexes and advanced medical complexes for cell and gene therapy to the Hwasun Vaccine Special Zone in Jeonnam.
Thermo Fisher, a global science company, has solutions that support the entire workflow from research to bioprocessing and commercialization of cell and gene therapies.